97. 潰瘍性大腸炎
[臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03716388
(ClinicalTrials.gov)
December 1, 201821/10/2018Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UCFecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC : a Pilot StudyUlcerative Colitis Chronic Mild;Ulcerative Colitis Chronic ModerateBiological: Fecal Microbiota Transplantation;Drug: Mesalamine Granules;Other: Placebo infusion;Other: Placebo granulesDayanand Medical College and HospitalColitis & Crohn's Foundation (India)Recruiting18 Years75 YearsAll20Phase 3India
2NCT00326209
(ClinicalTrials.gov)
December 22, 200512/5/2006Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in RemissionA Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet FormulationUlcerative ColitisDrug: Encapsulated Mesalamine Granules (eMG)Bausch Health Americas, Inc.NULLCompleted18 YearsN/AAll393Phase 3United States
3NCT00746447
(ClinicalTrials.gov)
May 20053/9/2008Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative ColitisColitis, Ulcerative;RecurrenceDrug: mesalamine granulesDr. Falk Pharma GmbHNULLCompleted18 Years75 YearsBoth648Phase 3Germany